SimpleStep ELISA® kits for inflammation research

Easily quantify cytokines, growth factors, kinases, and other key inflammation proteins with flexible, highly specific ELISAs.

​Inflammation is a central component of immunity¹. It is a normal host defense mechanism that protects the host from infection by initiating pathogen killing and tissue repair processes as well as helping to restore homeostasis at infected sites ². 

Whilst inflammation plays an essential role in host defense, a chronic, low-grade inflammatory state is a pathological feature of a wide range of chronic conditions, such as type 2 diabetes. However, there is still uncertainty around the causality and degree to which inflammation contributes and serves as a risk factor for the development of disease, largely due to a lack of biomarkers of inflammation and how to interpret their patterns and changes^1,2.

Overview

• Simplestep ELISA^® kits
• Cytokines and growth factors
• Receptors, kinases, and cell signaling
• Complement pathway 
• Transcription factors and nuclear proteins 
• Products to support SARS-CoV-2 research
• SimpleStep ELISA​^® webinar: accuracy and speed when assessing COVID-19

Get fast, reproducible, and robust results for your high-throughput screening

We’ve developed the largest range of single-wash, 90-minute ELISAs to simplify your inflammation experiments. 

SimpleStep ELISA^®s offer an adaptable, scalable solution with a standardized protocol to easily allow automation. Our SimpleStep ELISA kits are extensively tested and validated in relevant, biological samples to guarantee reaction with the endogenous protein and avoid wasting time on irrelevant or incorrect results and troubleshooting. 

Most of our SimpleStep ELISA^® kits use recombinant antibodies, ensuring the best possible reproducibility to add confidence across large datasets and long-term studies.   

Progress your inflammation research faster without compromising performance.

Find your target

Cytokines and growth factors

Cytokines are small secreted proteins that are released cells that have a specific effect on interactions and communications between cells³. As they are key instigators and regulators of immune responses, they hold great potential as targets for new therapeutic strategies⁴. Accumulating evidence suggests cytokine storms, triggered by an imbalanced response by type 1 and type 2 T helper cells, play an important role in severe immune cases, including severe COVID-19 cases^5,6.

Browse our SimpleStep ELISA kits for the quantification of cytokines and growth factors.

​​

Receptors, kinases, and cell signaling

​​Current treatment for chronic inflammatory diseases is based on the inhibition of mediators that drive acute inflammation. However, evidence is suggesting a whole range of mediators, receptors, and intracellular signaling events are important and have an active role in orchestrating acute inflammatory resolution⁷.

Browse our SimpleStep ELISA kits for the quantification of receptors, kinases, and cell signaling proteins.

Complement pathway

The complement system is part of the innate immune system and is best known for providing a first line of defense against infection, is known to drive pathogenesis or contribute as an inflammatory amplifier of a disease trigger. An upsurge in complement drug discovery is driven by association of the complement system with common diseases however difficulties from lack of the lack of clarity around disease mechanism and unwanted side effects means few drugs have progressed to late-stage clinical studies⁸.

Browse our SimpleStep ELISA kits for the quantification of complement pathway proteins.

Transcription factors and nuclear proteins

Altered gene expression is fundamental in the caution of many human diseases, including immune disorders. Rapid advances in the understanding of the key molecular biology of transcription factors and the signal transduction mechanisms that regulate their activity have pioneered a new frontier for the rational development of drugs that regulate gene expression⁹. 

Browse our SimpleStep ELISA kits for the quantification of transcription factors and nuclear proteins.

You can view all of our assays for cytokines and growth factors; receptors, kinases, and cell signaling proteins; complement pathway proteins; and transcription factors and nuclear proteins.

Products to support SARS-CoV-2 research

​The outbreak of the SARS-CoV-2 coronavirus, which causes COVID-19, has resulted in an urgent need for diagnostics and vaccine development. To support you and your research during this pandemic, we have collated coronavirus information and resources and offer a variety of tools to help accelerate infectious disease research.

Simplestep^® ELISA webinar: accuracy and speed when assessing COVID-19

Fast, reproducible results are essential for supporting all aspects of coronavirus research. Our webinar showcases how SimpleStep ELISA® assays have evolved to deliver quick results and give the highest level of confidence in your data.​​

References

1. Minihane, A. M., Vinoy, S., Russell, W. R., et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. The British journal of nutrition. 114, 999–1012. (2015).
2. Calder, P.C., Ahluwalia, N., Albers, R., et al. A Consideration of Biomarkers to be Used for Evaluation of Inflammation in Human Nutritional Studies. British Journal of Nutrition 109, pp. S1-S34. (2013). 
3. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 45, 27–37. (2007).
4. Kopf, M., Bachmann, M. & Marsland, B. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9, 703–718 (2010).
5. Mehta, P., McAuley, D.F., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395, pp. 1033-1034. (2020)
6. Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Basic Res Cardiol.   115(3):31. (2020). 
7. Harada, M., Kamimura, D., Arima, Y., et al. Temporal Expression of Growth Factors Triggered by Epiregulin Regulates Inflammation Development. J Immunol 194, 1039-1046 (2015).
8. Gilroy, D., Lawrence, T., Perretti, M. et al. Inflammatory Resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3, 401–416 (2004).
9. Harris C. L. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol, 40, 125–140 (2018).